| Old Articles: <Older 2271-2280 Newer> |
|---|
 |
Pharmaceutical Executive
August 1, 2005 |
Backpage: Feet-on-the-Street Interview A new survey asked pharmaceutical reps how their job has been changing. One bit of good news: A few reps think it's easier to get past the receptionist's desk.   |
Pharmaceutical Executive
August 1, 2005 |
Direct to Consumer: The Campaign Conundrum An interview with Steve Girgenti, worldwide chairman and CEO of Ogilvy Healthworld on how pharma companies struggle to get local support for their global marketing campaigns. |
Pharmaceutical Executive
August 1, 2005
Jill Wechsler |
Washington Report: Treating Patents It may seem unusual that a court ruling challenging patent protections is considered a victory for Big Pharma. But the decision was supported by pharmaceutical companies, along with the Justice Department, as a way to spur biomedical research and new-drug development. |
Pharmaceutical Executive
August 1, 2005
Sarah Houlton |
Global Report: Big Disadvantage Is the European Commission's definition of market dominance too narrow? AstraZeneca thinks so. |
The Motley Fool
August 16, 2005
Karl Thiel |
New Life for Boston Life Sciences? The biotech's stock soars on news of potential approval of its imaging agent for Parkinson's and ADHD. Enthusiastic retail investors drove this week's huge move on the market, and those are the only folks who will be moving the stock for some time to come. |
The Motley Fool
August 12, 2005
Stephen D. Simpson |
Novo Nordisk Perks Up This leading insulin company rebounds from a sluggish first quarter. For investors willing to buy and hold a stock for years, Novo Nordisk could still be an interesting play on a serious and growing disease market. |
The Motley Fool
August 10, 2005
Jack Uldrich |
Does NanoCrystal Ball See All? There is promise in biotech Elan, but not for the reason you might think. Investors, take note. |
Nursing Management
August 2005
Regina Foley |
Learn to Speak Finance To best prepare for developing nursing budgets, know your volume base. Realize who and where your competition is and plan accordingly. |
The Motley Fool
August 10, 2005
Stephen D. Simpson |
A Greatbatch of High Energy Strong demand for implanted medical devices continues to spark growth for this battery and electrical component maker. The stock does offer a fairly unique way to play multiple growing medical markets. |
The Motley Fool
August 9, 2005
Stephen D. Simpson |
STERIS Still Looks Sickly Respectable free cash flow generation doesn't erase the more basic problem of flagging sales growth at this infection-prevention and -control company. |
| <Older 2271-2280 Newer> Return to current articles. |
